Sign In
Buy PCVX
$51.96
-0.150 (-0.288%)
At Close: Jun 23, 2026
Vaxcyte, Inc. $PCVX Shares Bought by Federated Hermes Inc.
04:02am, Sunday, 08'th Feb 2026
Federated Hermes Inc. raised its position in Vaxcyte, Inc. (NASDAQ: PCVX) by 6,856.3% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
04:05pm, Thursday, 05'th Feb 2026
SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside
SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten pu
Vaxcyte Announces Pricing of $550 Million Public Offering
11:33pm, Thursday, 29'th Jan 2026
SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of commo
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
10:30pm, Thursday, 29'th Jan 2026
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:06pm, Thursday, 29'th Jan 2026
SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering o
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
05:00pm, Thursday, 22'nd Jan 2026
VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study
SG Americas Securities LLC Buys 14,421 Shares of Vaxcyte, Inc. $PCVX
06:23am, Tuesday, 20'th Jan 2026
SG Americas Securities LLC increased its stake in Vaxcyte, Inc. (NASDAQ: PCVX) by 129.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange C
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of “Moderate Buy” by Brokerages
01:22am, Friday, 16'th Jan 2026
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. One research an
Vaxcyte's Chief Technical Ops Officer Sells Shares
10:17am, Saturday, 03'rd Jan 2026
The CTO sold 9,743 shares. The sale represented 28.9% of Dhaliwal's holdings.
Vaxcyte (NASDAQ:PCVX) Insider Harpreet Dhaliwal Sells 9,743 Shares
05:38am, Saturday, 03'rd Jan 2026
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) insider Harpreet Dhaliwal sold 9,743 shares of Vaxcyte stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $
Vaxcyte (NASDAQ:PCVX) SVP Elvia Cowan Sells 11,623 Shares
05:03am, Tuesday, 30'th Dec 2025
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) SVP Elvia Cowan sold 11,623 shares of the firm's stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $47.92,
This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%.
08:19am, Monday, 22'nd Dec 2025
Vaxcyte keeps its place among Mizuho Securities top picks entering 2026.
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Rating of “Moderate Buy” from Analysts
01:11am, Monday, 22'nd Dec 2025
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten brokerages that are covering the company, MarketBeat reports. One research analyst has rat
Assenagon Asset Management S.A. Buys 171,974 Shares of Vaxcyte, Inc. $PCVX
03:44am, Sunday, 21'st Dec 2025
Assenagon Asset Management S.A. raised its stake in Vaxcyte, Inc. (NASDAQ: PCVX) by 358.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and
